UOC
SNTI icon

UBS O'Connor’s Senti Biosciences Holdings SNTI Stock Holding History

UBS O'Connor’s Portfolio SNTI Stock Details SNTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,752
Closed -$667K – 998
2022
Q1 		$667K Buy
+6,752
New +$667K 0.01% 735

Other funds holding SNTI

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
IC
Intel Corp Santa Clara, California $621M AUM 34.06% 1-Year Est. Return
FMN
Financial Management Network Mission Viejo, California $697M AUM 21.37% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
KC
Kingfisher Capital Charlotte, North Carolina $437M AUM 41.72% 1-Year Est. Return

UBS O'Connor's SNTI Position: Q2 2022 in Review

UBS O'Connor sold out of Senti Biosciences Holdings (SNTI) in Q2 2022, closing a stake of 6,752 shares — an estimated $667K sold.

UBS O'Connor first reported a position in SNTI in Q1 2022 and held it in 1 quarter. The position peaked at $667K in Q1 2022. 22 funds tracked by Wall St. Rank hold SNTI as of Q2 2022.

  • UBS O'Connor reported no remaining Senti Biosciences Holdings position as of Q2 2022 after selling out during the quarter.
  • UBS O'Connor sold 6,752 Senti Biosciences Holdings shares in Q2 2022, an estimated $667K.
  • UBS O'Connor first reported a position in Senti Biosciences Holdings in Q1 2022 and held it in 1 quarter.
  • UBS O'Connor's Senti Biosciences Holdings position peaked at $667K in Q1 2022.
  • 22 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q2 2022.

Based on UBS O'Connor's 13F filing for Q2 2022, filed 12 Aug 2022.